News

Conference Coverage

Ripretinib for Patients With Advanced GISTs in Later-Line Therapy

02/24/2023

In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.

In a multicenter, retrospective...

02/24/2023

Oncology

News

01/19/2023

Allison Casey ;

Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.

Among patients with rectal...

01/19/2023

Oncology

News

Avapritinib Shows Potential for Patients With PDGRFA D842V-Mutant Gastrointestinal Stromal Tumors

12/20/2022

Allison Casey ;

In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.

In a phase 1/2 study,...

12/20/2022

Oncology

News

Laparoscopic Surgery Demonstrates Feasibility, Safety for Gastrointestinal Stromal Tumors

11/17/2022

Allison Casey ;

Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.

Study findings reveal...

11/17/2022

Oncology

News

Guadecitabine Fails to Meet Target Response Rate in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors

11/10/2022

Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.

Phase 2 trial results reveal...

11/10/2022

Oncology

News

Ripretinib Provides No PFS Benefit vs Sunitinib for Patients With Advanced Gastrointestinal Stromal Tumors

09/27/2022

Allison Casey ;

Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...

Second-line treatment with...

09/27/2022

Oncology

News

Trans-Anal Total Mesorectal Excision Technique Feasible for Rectal Gastrointestinal Stromal Tumors

09/20/2022

Allison Casey ;

In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.

In a retrospective study, the...

09/20/2022

Oncology

News

Comparison of Surgical Methods for Treating Gastrointestinal Stromal Tumors

08/04/2022

Allison Casey ;

Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.

Findings from a comparative...

08/04/2022

Oncology

News

Study Identifies Factors Associated With GIST Recurrence and Metastasis

08/03/2022

Allison Casey ;

Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.

Primary site of tumors, tumor...

08/03/2022

Oncology

News

Preoperative Controlling Nutritional Status Score Predicts Recurrence in Patients With Resected GIST

08/03/2022

Allison Casey ;

Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.

Study finds high preoperative...

08/03/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology